A publication on the prevalence of self-reported side effects in neuroendocrine tumour patients prescribed somatostatin analogues written by Catherine Bouvier, Tara Whyand and Philippa Davies was featured in the British Journal of Nursing in 2018. Somatostatin...
Did you know that we have produced factsheets for specific Primary Neuroendocrine Cancer sites? These factsheets share comprehensive information and are aimed at patients, healthcare professionals and anyone wanting to get a better understanding of Neuroendocrine...
NCUK Launches their Bridging the Gap Campaign, the second of our three ‘Gap’ Campaigns. What is the BRIDGING the Gap campaign? We are working towards and obtaining a dedicated Neuroendocrine care pathway to provide equitable, holistic, joined up care for...
All Neuroendocrine Cancer patients globally are invited to share their experiences and perspectives on how treatment decisions have been modified during the COVID-19 pandemic for them via a specially designed survey. The survey is available in English, French, Italian...
As with more common cancers, the earlier in the development of a primary cancer it is diagnosed, the higher the possibility of cure is. For Secondary Neuroendocrine Cancer there is no cure – HOWEVER, this does not necessarily make this a terminal diagnosis. No...
